Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Entresto, Enerzair, 2 More HIF-PH Inhibitors OK'ed for Listing on August 26
August 19, 2020
- 22 Firms Get Approval for Lyrica Generics towards December Listing, Pfizer AG Included
August 18, 2020
- MHLW Grants Orphan Drug Status to Janssen’s Ibrutinib, 6 Other APIs
August 18, 2020
- Kaken’s Axillary Hyperhidrosis Drug, JT’s HIF-PH Inhibitor Up for MHLW Panel Review on Aug. 27
August 17, 2020
- MHLW Urges Trade Groups to Ensure Stable Supply of Povidone-Iodine Products
August 17, 2020
- AstraZeneca to Supply 120 Million Doses of COVID-19 Vaccine to Japan
August 11, 2020
- Japan to Grant Total of 90 Billion Yen to 6 Firms for COVID-19 Vaccine Production
August 11, 2020
- MHLW Warns of COVID-Tied Cyberattacks, Urges Companies to Boost Measures
August 7, 2020
- Tsutomu Iuchi to Lead MHLW's Medical Economics Division
August 6, 2020
- NIBIOHN, US Biotech to Develop COVID-19 Replicon RNA Vaccine; Japan PII Eyed Next Summer
August 5, 2020
- Japan Sketches Out Stable API Supply Measures, Set to Pick Key Drugs from 551 Candidates by March-End
August 4, 2020
- Tetsunari Kihira Appointed as Pharmaceutical Management Director
August 4, 2020
- Pfizer to Supply COVID-19 Vaccine Doses for 60 Million People in Japan
August 3, 2020
- PMDA Reviewing Safety Risks for Plaquenil, Relumina
August 3, 2020
- PMDA Provided Preliminary Info on MID-NET Use for Free in “Just Under 10 Cases”: Official
July 31, 2020
- MHLW Finds 57 Suspected Violations in Drug Detailing Activities in FY2019
July 30, 2020
- AMED’s Drug Discovery Library under CiCLE Program Ready to Start Operations
July 30, 2020
- AMED Selects 2 Anti-COVID-19 Projects under CiCLE Grant Program
July 30, 2020
- HPV Vaccines Clinically Significant in Japan, PMDA Says in Silgard 9 Review Report
July 28, 2020
- Dexamethasone Added to MHLW’s COVID-19 Guide
July 27, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…